Antibody humanization is a key step in the preclinical phase of the development of therapeutic antibodies, originally developed and tested in non-human models (most typically, in mouse). The standard technique of Complementarity-Determining Regions (CDR) grafting into human Framework Regions of germline sequences has some important drawbacks, in that the resulting sequences often need further back-mutations to ensure functionality and/or stability. Here we propose a new method to characterize the statistical distribution of the sequences of the variable regions of human antibodies, that takes into account phenotypical correlations between pairs of residues, both within and between chains. We define a "humanness score" of a sequence, compari...
Immunogenicity is an important concern for therapeutic antibodies during drug development. By analyz...
The work presented in this thesis focusses on the sequence and structural analysis of antibodies and...
Broadly neutralizing antibodies against HIV are rare; most patients never develop them at detectable...
Antibody humanization is a key step in the preclinical phase of the development of therapeutic antib...
Motivation: Monoclonal antibody therapeutics are often produced from non-human sources (typically mu...
In antibody humanization, complementarity determining regions from a 'donor' antibody are often graf...
<div><p>Antibody development is still associated with substantial risks and difficulties as single m...
Antibody therapeutics are usually developed in animals, commonly in mouse, and then they are humaniz...
Antibody development is still associated with substantial risks and difficulties as single mutations...
Chimeric, humanized and human antibodies have successively been exploited as therapeutics because th...
Monoclonal antibodies are playing an increasing role in both human and animal health. Different stra...
Monoclonal antibodies (mAbs) are widely used due to their exquisite specificity and once were hailed...
The work presented in this thesis focusses on the sequence and structural analysis of antibodies and...
The work presented in this thesis focuses on the sequence and structural analysis of antibodies and ...
<div><p>1-17-2 is a rat anti-human DEC-205 monoclonal antibody that induces internalization and deli...
Immunogenicity is an important concern for therapeutic antibodies during drug development. By analyz...
The work presented in this thesis focusses on the sequence and structural analysis of antibodies and...
Broadly neutralizing antibodies against HIV are rare; most patients never develop them at detectable...
Antibody humanization is a key step in the preclinical phase of the development of therapeutic antib...
Motivation: Monoclonal antibody therapeutics are often produced from non-human sources (typically mu...
In antibody humanization, complementarity determining regions from a 'donor' antibody are often graf...
<div><p>Antibody development is still associated with substantial risks and difficulties as single m...
Antibody therapeutics are usually developed in animals, commonly in mouse, and then they are humaniz...
Antibody development is still associated with substantial risks and difficulties as single mutations...
Chimeric, humanized and human antibodies have successively been exploited as therapeutics because th...
Monoclonal antibodies are playing an increasing role in both human and animal health. Different stra...
Monoclonal antibodies (mAbs) are widely used due to their exquisite specificity and once were hailed...
The work presented in this thesis focusses on the sequence and structural analysis of antibodies and...
The work presented in this thesis focuses on the sequence and structural analysis of antibodies and ...
<div><p>1-17-2 is a rat anti-human DEC-205 monoclonal antibody that induces internalization and deli...
Immunogenicity is an important concern for therapeutic antibodies during drug development. By analyz...
The work presented in this thesis focusses on the sequence and structural analysis of antibodies and...
Broadly neutralizing antibodies against HIV are rare; most patients never develop them at detectable...